Proteomic signatures of canine myxomatous mitral valve disease reveal candidate biomarkers associated with progression from stage B2 to stage C
Abstract
Abstract Background Myxomatous mitral valve disease (MMVD) is the most prevalent acquired cardiac disease in dogs. Echocardiography is widely used for disease staging. However, the availability of biomarkers reflecting the molecular basis of disease progression remains limited. The objective was to characterize plasma proteomic profiles in dogs with American College of Veterinary Internal Medicine (ACVIM) MMVD stages B2 and C, identify candidate biomarkers associated with disease progression, and investigate their potential interactions with commonly used cardiovascular drugs. Results Plasma samples from 41 dogs with MMVD stage B2 (26) and stage C (15) were analyzed with label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS), and the candidate biomarkers were identified. Dogs with stage C MMVD had significantly dilated left ventricles, as represented by a higher normalized left ventricular internal diameter in diastole (LVIDDN; P
How strong is the evidence?
Evidence Hub reads this as a preprint, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.